Conclusion
vascular dysfunction, CHF
CHF
We found a significant reduction in tissue sodium content after 1 and 3 months treatment with the SGLT2 inhibitor empagliflozin. Our data support the concept that increased skin sodium content in patients with CHF has clinically relevant pathogenic effects, leading to cardiac as well as vascular dysfunction and consequently to CHF. The reduction of extravascular sodium content may reflect a decrease in subclinical micro-oedema or/and in non-osmotic bound sodium, both reported to impair left ventricular function.